Table 2.

Fasting glucose and insulin levels with corresponding treatment regimens

Day after hospitalization	FG mg/dL (mmol/L)	Insulin μU/mL	Treatment regimen (Analysis by CGM) [Analysis of C-peptide responses to each meal]
1			Asp 4–4-4, stopped insulin glargine
2	62 (3.4)	4500
3	47 (2.6)
5	55 (3.1)
8			Stopped Asp from dinner
10	358 (19.9)	2500
16	362 (20.1)		Start Asp 4–6-4
20	61 (3.4)		Stopped Asp, start RHI 4–4-4
30			RHI 4–4-4, add LIRA 0.3 mg QD
38	77 (4.3)		RHI 4–4-4 + LIRA 0.6 mg QD
41			RHI 3–3-3 + LIRA 0.9 mg QD
43	65 (3.6)	3570
45	79 (4.4)		Stopped RHI, start Lis 3–3-3 + LIRA 0.9 mg QD
51	52 (2.9)		Lis 3–3-3 + LIRA 0.9 mg QD, add Voglibose 0.2 mg QD
53	51 (2.8)	3500	(CGM in Fig. 2a)
54			[C-peptide measurement in Fig. 3]
56	63 (3.5)		Lis 2–3-3 + LIRA 0.9 mg QD + Voglibose 0.2 mg QD
58	68 (3.8)		Lis 2–3-3 + LIRA 0.9 mg QD + Voglibose 0.2 mg QD, add Mitiglinide 10 mg TID
59	46 (2.6)		LIRA 0.9 mg QD + Voglibose 0.2 mg QD + Mitiglinide 10 mg TID, stopped Lis [C-peptide measurement in Fig. 3]
61	91 (5.1)
63	95 (5.3)		(CGM in Fig.2b)
66	167 (9.3)	2640
67	100 (5.6)

FG fasting glucose, Asp Insulin aspart, RHI regular human insulin, LIRA liraglutide, Lis Insulin lispro, QD daily, TID three times a day, CGM continuous glucose monitoring